Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: wolfdog2 who wrote (3283)	6/14/1999 10:04:00 AM
From: j_fir2	Respond to of 10280

From Bloomberg on UCB: url to follow: Hoechst AG's Allegra allergy pill is already stunting Zyrtec's sales growth, says Cox, and could soon overtake it as the second most popular U.S. allergy medicine. ''The reason UCB is finding it hard to keep sales of Zyrtec growing is Allegra,'' he says. Sepracor Inc., a U.S. biotechnology company which makes improved versions of existing pills, said last year it received a patent for Cetirizine, a new version of Zyrtec. UCB recently said it obtained the license to sell the drug in Europe until 2013, but cannot sell it in the U.S. or Japan. Sepracor also unveiled a study recently that showed its improved version of Johnson and Johnson Corp.'s Hismanal allergy drug could be more effective than Schering's Claritin. The drug is still in preliminary clinical trials, but it's another example of a future competitor for Zyrtec.